TY - JOUR
T1 - Breast cancer in BRCA mutation carriers
T2 - Medical treatment
AU - Milani, Andrea
AU - Geuna, Elena
AU - Zucchini, Giorgia
AU - Aversa, Caterina
AU - Martinello, Rossella
AU - Montemurro, Filippo
PY - 2016/10/1
Y1 - 2016/10/1
N2 - About 10% of breast cancers are associated with the inheritance of autosomal dominant breast cancer susceptibility alleles BRCA1 and BRCA2. Until recently, the medical management of BRCA mutation-associated breast cancer has not differed from that of the sporadic breast cancer counterpart. However, there is mounting evidence that this molecular alteration confers sensitivity or resistance to systemic therapies that can be exploited in terms of medical management. For example, studies support the use of platinum salts chemotherapy in BRCA mutated cancers. Moreover, a number of targeted therapies are showing activity in BRCA mutation carriers. Above all, BRCA defective tumor cells are particularly sensitive to Poly(ADP-ribose) polymerase (PARP) inhibitors. This review will summarize the state of the art of the medical treatment of breast cancer in BRCA mutation carriers, with a particular focus on chemotherapies and targeted therapies.
AB - About 10% of breast cancers are associated with the inheritance of autosomal dominant breast cancer susceptibility alleles BRCA1 and BRCA2. Until recently, the medical management of BRCA mutation-associated breast cancer has not differed from that of the sporadic breast cancer counterpart. However, there is mounting evidence that this molecular alteration confers sensitivity or resistance to systemic therapies that can be exploited in terms of medical management. For example, studies support the use of platinum salts chemotherapy in BRCA mutated cancers. Moreover, a number of targeted therapies are showing activity in BRCA mutation carriers. Above all, BRCA defective tumor cells are particularly sensitive to Poly(ADP-ribose) polymerase (PARP) inhibitors. This review will summarize the state of the art of the medical treatment of breast cancer in BRCA mutation carriers, with a particular focus on chemotherapies and targeted therapies.
KW - BRCA1
KW - BRCA2
KW - Breast neoplasms
KW - Drug therapy
KW - Genes
KW - Molecular targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84983652629&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983652629&partnerID=8YFLogxK
M3 - Review article
AN - SCOPUS:84983652629
VL - 68
SP - 557
EP - 565
JO - Minerva Ginecologica
JF - Minerva Ginecologica
SN - 0026-4784
IS - 5
ER -